What is Wolfe Research's price target for SILK?

Wolfe Research's latest stated price target for Silk Road Medical Inc. (SILK) is $27, from its action on May 15, 2023.

What is Wolfe Research's rating on SILK?

Wolfe Research rates SILK Peer Perform, a neutral rating, as of Oct 24, 2023.

When did Wolfe Research last change its view on SILK?

On Oct 24, 2023, Wolfe Research upgrades to Peer Perform from Underperform.

Wolfe Research SILK price target and rating history

Silk Road Medical Inc. (SILK) · Health Care

Wolfe Research rates Silk Road Medical Inc. (SILK) Peer Perform with a $27 price target, as of its latest action on Oct 24, 2023. It has published 4 rating actions on SILK since April 2022, including 1 upgrade and 2 downgrades.

Current rating: Peer Perform
Price target: $27
Median target, all firms: Too few
Actions on SILK: 4

Wolfe Research price target on SILK

Wolfe Research price target on SILK, each point a stated target, April 2022 to May 2023.

Every Wolfe Research rating on SILK

Oct 24, 2023
UpgradeWolfe Research upgrades to Peer Perform from Underperform
May 15, 2023
DowngradeWolfe Research downgrades to Underperform from Peer Perform, price target $27
Feb 7, 2023
DowngradeWolfe Research downgrades to Peer Perform from Outperform
Apr 6, 2022
InitiateWolfe Research starts coverage at Outperform, price target $48

Questions about Wolfe Research and SILK

What is Wolfe Research's price target for SILK?: Wolfe Research's latest stated price target for Silk Road Medical Inc. (SILK) is $27, from its action on May 15, 2023.
What is Wolfe Research's rating on SILK?: Wolfe Research rates SILK Peer Perform, a neutral rating, as of Oct 24, 2023.
When did Wolfe Research last change its view on SILK?: On Oct 24, 2023, Wolfe Research upgrades to Peer Perform from Underperform.

More SILK rating histories

All Wolfe Research ratings SILK news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.